The company in question is, Exelixis, Inc. (NASDAQ:EXEL) currently with a stock price of 11.59 (-2.69% today). The market cap for Exelixis, Inc. is 2791.94, and is in the sector Healthcare, and Biotechnology industry. The target price for Exelixis, Inc. is 12.67. Currently Exelixis, Inc. is trading with a P/E of *TBA, and a forward P/E of *TBA. Average volume for Exelixis, Inc. is 6520.14 and so far today it is 3310587.
Performance in the last year for Exelixis, Inc. has been 112.68%. For EPS growth, Exelixis, Inc. has seen a growth of 41.30%, and is looking to grow in the next year to 86.90%. More long term stats show that EPS growth has been 0.90% over the last five years and could be *TBA for the next five years. Exelixis, Inc. has seen sales growth quarter over quarter at 353.70%, with EPS growth quarter over quarter at 27.00%. The 20-day simple moving average is -4.90%, with the 200-day simple moving average coming to 60.54%.
Since the IPO date for Exelixis, Inc. on the 4/17/2000, Exelixis, Inc. has seen performance year to date to be 111.17%. With Exelixis, Inc. trading at 11.59, the dividend yield is *TBA, and the EPS is -0.84.
So could Exelixis, Inc., be undervalued? Well as said before P/E is *TBA. The PEG is *TBA, P/S is 39.05 and the P/B is at *TBA. The P/cash is 8.51, with P/free cash flow at 48.14.
Exelixis, Inc. ability to deal with debt shows that the current ratio is 1.8, and the quick ratio is 1.8. This is with long term debt/equity at *TBA, and total debt/equity at *TBA.
In terms of margins, Exelixis, Inc. has a gross margin of 93.40%, an operating margin of *TBA and a profit margin of *TBA.Payout ratio for Exelixis, Inc. is *TBA. Return on assets come to -45.50% with return on investment coming to -43.80%.
Insider ownership for Exelixis, Inc., is at 0.60% and institutional ownership comes to 83.50%. Outstanding shares are at 234.42. While shares float is 204.72. The float short is currently 10.92%, and short ratio is 3.43.